Genfit Archives

News and Trends 28 Mar 2017

Why did Biotech Beat Pharma to Bring the First Gene Therapy to Market?

Pharma would seemingly best biotech in any competition. A few CEOs explain why it left the honor of “The First Gene Therapy” to biotech. On July 20, 2012, the western world’s first gene therapy, Glybera, received marketing authorization from the EMA. The treatment was designed and developed by uniQure as one-off treatment for Lipoprotein Lipase Deficiency (LPLD), a […]

March 28, 2017 - 5 minutesmins - By Evelyn Warner

News and Trends 26 Dec 2016

The Largest Deals, Fundraising and Exits of 2016 in European Biotech

Curious about which technologies have attracted the most cash in biotech finance this year? Here’s a list of the most impressive cash movements of 2016 in Europe. Believe it or not, 2016 has been the worst year for biotech finance in a decade. The political scene has become unfavorable for British biotech after Brexit, and the uncertainty raised by […]

December 26, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Nov 2016

Green Light for Genfit to Tackle another Liver Disease

The FDA has cleared Genfit’s IND application to treat a second liver disease with a big unmet clinical need. With this new step forward, the company gets even closer to become the leader in liver disease treatments. After a very successful fundraising last week, Genfit is kicking off the week with good news from the […]

November 7, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 20 Sep 2016

Genfit’s Non-Invasive Diagnostic could unlock the NASH Market

Genfit reinforced its leading place in the race to find a cure for NASH when it announced this morning the launch of a program to validate their new diagnostic tool. Genfit is already leading in the development of a cure for Non-Alcoholic Stato-Hepatitis (NASH) with its candidate, Elafibranor, which is in Phase III trials. Now, the French €600M biopharma has […]

September 20, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 31 Mar 2016

Beyond NASH: Genfit jumps into another Critical Liver Condition

Genfit is extending the applications of its star candidate, Elafibranor, to a second liver disease – Primary Biliary Cholangitis (PBC), a rare condition with high unmet medical needs. Genfit from Lille (France) has been in the spotlight because of its phase III candidate for NASH – something we discussed with its CEO, Jean-François Mouney. Apparently, all the […]

March 31, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 11 Mar 2016

Genfit Has Enroled its First Patient in a NASH Phase III Trial

Genfit (France) has enroled their first patient in the highly anticipated phase III trial (RESOLVE-IT) for NASH, a fatty-liver disease currently without any approved treatment. This is good news for Genfit, which managed to kickstart a phase III trial for their lead candidate, Elafibranor, just one year after the read-out of the phase IIb results. There […]

March 11, 2016 - 2 minutesmins - By Denise Neves Gameiro

News and Trends 12 Jan 2016

10 Hot European Biotechs to watch in 2016

Looking forward to 2016, I wondered which Biotechs I would watch closely. Here’s my list (which is not meant to be extensive and is in no particular order): 1. Immunocore – Oxford, UK Immunocore is developing TCR-based immuno-oncology treatments and has raised nearly €300M ($320M) in its last round of private fundraising – a pure anomaly […]

January 12, 2016 - 6 minutesmins - By Philip Hemme

News and Trends 10 Dec 2015

Infographic: The Anatomy of European Biotech

Which part of our body do European biotechs prefer to target? And how diversified are the biotech companies in Europe nowadays? Let’s take the human body to know who works on what. From the brain to the kidney, from Genfit to Cellectis…. Here is an infographic-based overview of some of the target areas that European […]

December 10, 2015 - 1 minutemin - By Nicolas Sainte-Foie

News and Trends 16 Nov 2015

Interview with the CEO of Genfit – The Billion Euro Liver Biotech on its phase III NASH Drug

Interview with Jean-François Mouney (Chairman and CEO of Genfit) at the ‘Liver Meeting 2015‘ congress for the American Association for the study of Liver disease (AASLD) on Friday in San Francisco (US). Genfit is the European leader in NASH research (Non-alcoholic steatohepatitis), today making the news again at AASLD in San Francisco. The company, which […]

November 16, 2015 - 5 minutesmins - By Dani Bancroft

News and Trends 19 May 2015

Boehringer kindles NASH treatments with Pharmaxis’ drug acquisition

Does NASH mean anything to you? You should be vigilant about this market as it could be the source of next major blockbusters. This new and latest acquisition by Boehringer, is yet another sign of the growing interest for NASH treatments, already chased by companies such as Intercept, Genfit or Gilead. NASH, or non-alcoholic steatohepatitis, is regarded as […]

May 19, 2015 - 4 minutesmins - By Joachim Eeckhout

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Genfit

Why did Biotech Beat Pharma to Bring the First Gene Therapy to Market?

The Largest Deals, Fundraising and Exits of 2016 in European Biotech

Green Light for Genfit to Tackle another Liver Disease

Genfit’s Non-Invasive Diagnostic could unlock the NASH Market

Beyond NASH: Genfit jumps into another Critical Liver Condition

Genfit Has Enroled its First Patient in a NASH Phase III Trial

10 Hot European Biotechs to watch in 2016

Infographic: The Anatomy of European Biotech

Interview with the CEO of Genfit – The Billion Euro Liver Biotech on its phase III NASH Drug

Boehringer kindles NASH treatments with Pharmaxis’ drug acquisition

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!